SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-14-006112
Filing Date
2014-02-11
Accepted
2014-02-11 07:32:59
Documents
1
Period of Report
2014-02-07

Document Format Files

Seq Description Document Type Size
1 rrd401910.html 4  
1 rrd401910.xml 4 5736
  Complete submission text file 0001181431-14-006112.txt   7087
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Issuer) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3344 N. TORREY PINES COURT, SUITE 200 LA JOLLA CA 92037
Business Address
Booth Mark D (Reporting) CIK: 0001470885 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33415 | Film No.: 14591306